NCT07518862 Heart Rate VAriability as a MaRker for tItrATing hIgh flOw Nasal Cannula Therapy
| NCT ID | NCT07518862 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Health Network, Toronto |
| Condition | Respiratory Failure |
| Study Type | OBSERVATIONAL |
| Enrollment | 20 participants |
| Start Date | 2026-05-26 |
| Primary Completion | 2026-11 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 20 participants in total. It began in 2026-05-26 with a primary completion date of 2026-11.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
High-flow nasal cannula is a type of non-invasive respiratory support that helps patients breathe more comfortably. Because the flow is high, it can deliver more oxygen to the lungs and make breathing easier by reducing the effort needed to breathe. However, the best strategy to determine the best oxygen flow rate remains uncertain. Reducing flow rates prematurely can increase work of breathing and prolong ICU stay, while unnecessary prolongation can increase costs. Currently, evidence to guide titration is limited. Heart rate variability is the natural variation in the time between each heartbeat. Heart rate variability reflects the level of autonomic nervous system activity in response to stress. The autonomic nervous system is the part of the nervous system that automatically controls how heart rate speeds up and slows down. When heart rate variability is higher, it indicates that the system is able to adjust to changes in the body, including stress. However, when heart rate variability is low, it indicates that the system is constrained and in a state of stress. The VARIATION study is designed to characterize how heart rate variability goal of this observational study is to learn whether heart rate variability can serve as a marker of the appropriateness of high flow nasal cannula flow support during flow titration in patients with respiratory failure. The main question it aims to answer is: Does heart rate variability change before other conventional respiratory signs when there are changes in respiratory function due to inadequate flow rate? Participants already on high flow nasal cannula as part of their regular medical care will: 1. Undergo a stepwise decrease in high flow nasal cannula flow rate. 2. Be recorded continuously with electrocardiogram and electrical impedance tomography.
Eligibility Criteria
Inclusion Criteria: * Age \> 18 * Currently receiving High-Flow Nasal Cannula Therapy Exclusion Criteria: * FiO2 ≥ 90% * Pacemaker rhythm or presence of atrial fibrillation * Post-cardiac surgery patients * Contra-indications to electrical impedance tomography (EIT) and/or electrocardiogram (ECG) (active implantable medical device, burns, thoracic wounds limiting electrode placement) * Non-English-speaking
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07518862 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Respiratory Failure. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07518862 currently recruiting?
Yes, NCT07518862 is actively recruiting participants. Contact the research team at rongyu.jin@uhn.ca for enrollment information.
Where is the NCT07518862 trial being conducted?
This trial is being conducted at Toronto, Canada.
Who is sponsoring the NCT07518862 clinical trial?
NCT07518862 is sponsored by University Health Network, Toronto. The trial plans to enroll 20 participants.